Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. (2022)

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.xcrm.2022.100541

PubMed Identifier: 35732148

Publication URI: http://europepmc.org/abstract/MED/35732148

Type: Journal Article/Review

Volume: 3

Parent Publication: Cell reports. Medicine

Issue: 6

ISSN: 2666-3791